MNKD Mannkind Earnings and EPS analysis

Relative Growth: Rel. Growth: 35

Relative Strength: Rel. Strength: 25

Relative Valuation: Rel. Valuation: 19

Relative Profitability: Rel. Profitability: 32

EPS in 2026 (TTM): -$0.07

Last Report Period Date: Mar 31, 2026

Based on the company's latest reports for March 2026, the current 12-month EPS is -$0.07. Mannkind's earnings per share in 2025 was reported at $0.02, marking a decline from $0.1 in 2024. In the quarterly report ending on Mar 31, 2026, MNKD's earnings per share amounted to -$0.05.

MNKD earnings history

Historical annual and quarterly earnings per share (EPS) data for Mannkind

EPS (TTM)

-$0.07

EPS Growth YoY (Quarterly)

-225%

EPS (Quarterly)

-$0.05

EPS Growth (Quarterly)

Mannkind had an yealy earnings per share of $0.02, showing a decline of 80% from $0.1 recorded in 2024. The quarterly earnings per share for the period ending Mar 31, 2026, was -$0.05, showing a 225% decline compared to the same quarter last year. The trailing twelve months EPS for MNKD is -$0.07 as of March 2026. Mannkind's full-year EPS for 2024 was $0.1, a 350% rise compared to the previous year.

MNKD earnings chart

MNKD EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

-225%

EPS growth YoY

-80%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

Mannkind has recorded a decline in earnings per share of 225% in the past 12 months (YoY, quarterly).

MNKD Earnings Waterfall

Breakdown of revenue, profit and net income for Mannkind

MNKD Earnings vs Peers

What are the earnings of MNKD compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
PFE Pfizer Inc	19.79	-3.5%	-37.4%	-3.7%
HALO Halozyme Therapeutics Inc	24.25	-24.6%	21.3%	22.7%
MRK Merck & Co Inc	33.36	8%	8.4%	21.2%
LLY ELI LILLY & Co	40.35	95.6%	49.2%	27.5%
NKTR Nektar Therapeutics	N/A	-12.1%	N/A	N/A
MNKD Mannkind Corp	N/A	-80%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.